Peptidome analysis of cerebrospinal fluid by LC-MALDI MS

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Hölttä, Mikko ^a   Zetterberg, Henrik ^a   Mirgorodskaya, Ekaterina ^a   Mattsson, Niklas ^a   Blennow, Kaj ^a   Gobom, Johan ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR LIKE PROTEIN 1; AMYLOID PRECURSOR PROTEIN; CHROMOGRANIN A; CHROMOGRANIN B; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEUROPEPTIDE Y; PEPTIDE; PRION PROTEIN; SECRETOGRANIN 3; SECRETOGRANIN II; UNCLASSIFIED DRUG;

ACETYLATION; AMIDATION; AMINO ACID SEQUENCE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; DEAMINATION; HUMAN; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OXIDATION; PEPTIDE ANALYSIS; PEPTIDOMICS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN CLEAVAGE; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SULFATION;

AMINO ACID SEQUENCE; CEREBROSPINAL FLUID PROTEINS; CHROMATOGRAPHY, LIQUID; DATABASES, PROTEIN; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEOME; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84864643743     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042555     Document Type: Article

References (54)

1. Zhang J, Goodlett DR, Montine TJ, ((2005)) Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases. J Alzheimers Dis 8:377-386.
2. Hokfelt T, Broberger C, Xu ZQ, Sergeyev V, Ubink R, et al. ((2000)) Neuropeptides-an overview. Neuropharmacology 39:1337-1356.
3. Johanson CE, Duncan JA 3rd, Klinge PM, Brinker T, Stopa EG, et al. ((2008)) Multiplicity of cerebrospinal fluid functions: New challenges in health and disease. Cerebrospinal Fluid Res 5:10.
4. Harrington MG, Fonteh AN, Oborina E, Liao P, Cowan RP, et al. ((2009)) The morphology and biochemistry of nanostructures provide evidence for synthesis and signaling functions in human cerebrospinal fluid. Cerebrospinal Fluid Res 6:10.
5. Maccarrone G, Milfay D, Birg I, Rosenhagen M, Holsboer F, et al. ((2004)) Mining the human cerebrospinal fluid proteome by immunodepletion and shotgun mass spectrometry. Electrophoresis 25:2402-2412.
6. Pan S, Zhu D, Quinn JF, Peskind ER, Montine TJ, et al. ((2007)) A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics 7:469-473.
7. Schutzer SE, Liu T, Natelson BH, Angel TE, Schepmoes AA, et al. ((2010)) Establishing the proteome of normal human cerebrospinal fluid. PLoS One 5:e10980.
8. Sickmann A, Dormeyer W, Wortelkamp S, Woitalla D, Kuhn W, et al. ((2000)) Identification of proteins from human cerebrospinal fluid, separated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 21:2721-2728.
9. Thouvenot E, Urbach S, Dantec C, Poncet J, Seveno M, et al. ((2008)) Enhanced detection of CNS cell secretome in plasma protein-depleted cerebrospinal fluid. J Proteome Res 7:4409-4421.
10. Wenner BR, Lovell MA, Lynn BC, ((2004)) Proteomic analysis of human ventricular cerebrospinal fluid from neurologically normal, elderly subjects using two-dimensional LC-MS/MS. J Proteome Res 3:97-103.
11. Xu J, Chen J, Peskind ER, Jin J, Eng J, et al. ((2006)) Characterization of proteome of human cerebrospinal fluid. Int Rev Neurobiol 73:29-98.
12. Yuan X, Desiderio DM, ((2005)) Proteomics analysis of prefractionated human lumbar cerebrospinal fluid. Proteomics 5:541-550.
13. Zhang J, Goodlett DR, Peskind ER, Quinn JF, Zhou Y, et al. ((2005)) Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging 26:207-227.
14. Zougman A, Pilch B, Podtelejnikov A, Kiehntopf M, Schnabel C, et al. ((2008)) Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res 7:386-399.
15. Berven FS, Kroksveen AC, Berle M, Rajalahti T, Flikka K, et al. ((2007)) Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. Proteomics Clin Appl 1:699-711.
16. Stark M, Danielsson O, Griffiths WJ, Jornvall H, Johansson J, ((2001)) Peptide repertoire of human cerebrospinal fluid: novel proteolytic fragments of neuroendocrine proteins. J Chromatogr B Biomed Sci Appl 754:357-367.
17. Yuan X, Desiderio DM, ((2005)) Human cerebrospinal fluid peptidomics. J Mass Spectrom 40:176-181.
18. Liotta LA, Petricoin EF, ((2006)) Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 116:26-30.
19. Villanueva J, Martorella AJ, Lawlor K, Philip J, Fleisher M, et al. ((2006)) Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol Cell Proteomics 5:1840-1852.
20. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, et al. ((2006)) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116:271-284.
21. Lopez MF, Mikulskis A, Kuzdzal S, Bennett DA, Kelly J, et al. ((2005)) High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem 51:1946-1954.
22. Jahn H, Wittke S, Zurbig P, Raedler TJ, Arlt S, et al. ((2011)) Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLoS One 6:e26540.
23. Blennow K, Fredman P, Wallin A, Gottfries CG, Karlsson I, et al. ((1993)) Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. Eur Neurol 33:129-133.
24. Jurado R, Walker HK, ((1990)) Cerebrospinal Fluid.
25. Huhmer AF, Biringer RG, Amato H, Fonteh AN, Harrington MG, ((2006)) Protein analysis in human cerebrospinal fluid: Physiological aspects, current progress and future challenges. Dis Markers 22:3-26.
26. Shores KS, Knapp DR, ((2007)) Assessment approach for evaluating high abundance protein depletion methods for cerebrospinal fluid (CSF) proteomic analysis. J Proteome Res 6:3739-3751.
27. Huang HL, Stasyk T, Morandell S, Mogg M, Schreiber M, et al. ((2005)) Enrichment of low-abundant serum proteins by albumin/immunoglobulin G immunoaffinity depletion under partly denaturing conditions. Electrophoresis 26:2843-2849.
28. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, et al. ((2003)) Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2:1096-1103.
29. Yu W, Vath JE, Huberty MC, Martin SA, ((1993)) Identification of the facile gas-phase cleavage of the Asp-Pro and Asp-Xxx peptide bonds in matrix-assisted laser desorption time-of-flight mass spectrometry. Anal Chem 65:3015-3023.
30. Gu CG, Somogyi A, Wysocki VH, Medzihradszky KF, ((1999)) Fragmentation of protonated oligopeptides XLDVLQ (X = L, H, K or R) by surface induced dissociation: additional evidence for the 'mobile proton' model. Analytica Chimica Acta 397:247-256.
31. Vizcaino JA, Cote R, Reisinger F, Barsnes H, Foster JM, et al. ((2010)) The Proteomics Identifications database: 2010 update. Nucleic Acids Res 38:D736-742.
32. Blennow K, de Leon MJ, Zetterberg H, ((2006)) Alzheimer's disease. Lancet 368:387-403.
33. Blennow K, Hampel H, Weiner M, Zetterberg H, ((2010)) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6:131-144.
34. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K, ((2006)) Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res 5:1010-1016.
35. Andreasson U, Portelius E, Andersson ME, Blennow K, Zetterberg H, ((2007)) Aspects of beta-amyloid as a biomarker for Alzheimer's disease. Biomark Med 1:59-78.
36. Takeda K, Araki W, Akiyama H, Tabira T, ((2004)) Amino-truncated amyloid beta-peptide (Abeta5-40/42) produced from caspase-cleaved amyloid precursor protein is deposited in Alzheimer's disease brain. FASEB J 18:1755-1757.
37. Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, et al. ((2011)) A novel pathway for amyloid precursor protein processing. Neurobiol Aging 32:1090-1098.
38. Mattsson N, Rajendran L, Zetterberg H, Gustavsson M, Andreasson U, et al. ((2012)) BACE1 Inhibition Induces a Specific Cerebrospinal Fluid beta-Amyloid Pattern That Identifies Drug Effects in the Central Nervous System. PLoS One 7:e31084.
39. Yanagida K, Okochi M, Tagami S, Nakayama T, Kodama TS, et al. ((2009)) The 28-amino acid form of an APLP1-derived Abeta-like peptide is a surrogate marker for Abeta42 production in the central nervous system. EMBO Mol Med 1:223-235.
40. Rogge G, Jones D, Hubert GW, Lin Y, Kuhar MJ, ((2008)) CART peptides: regulators of body weight, reward and other functions. Nat Rev Neurosci 9:747-758.
41. Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, et al. ((1998)) Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393:72-76.
42. Benarroch EE, ((2009)) Neuropeptide Y: its multiple effects in the CNS and potential clinical significance. Neurology 72:1016-1020.
43. Berger T, Reindl M, ((2000)) Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis. J Neural Transm Suppl pp. 351-360.
44. Bartolomucci A, Possenti R, Mahata SK, Fischer-Colbrie R, Loh YP, et al. ((2011)) The extended granin family: structure, function, and biomedical implications. Endocr Rev 32:755-797.
45. Ruetschi U, Zetterberg H, Podust VN, Gottfries J, Li S, et al. ((2005)) Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol 196:273-281.
46. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, et al. ((2003)) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3:1486-1494.
47. Simonsen AH, McGuire J, Podust VN, Hagnelius NO, Nilsson TK, et al. ((2007)) A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dement Geriatr Cogn Disord 24:434-440.
48. Huang JT, Leweke FM, Oxley D, Wang L, Harris N, et al. ((2006)) Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 3:e428.
49. Mattsson N, Ruetschi U, Podust VN, Stridsberg M, Li S, et al. ((2007)) Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. J Neurochem 103:1932-1939.
50. Stoop MP, Dekker LJ, Titulaer MK, Burgers PC, Sillevis Smitt PA, et al. ((2008)) Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics 8:1576-1585.
51. Stoop MP, Dekker LJ, Titulaer MK, Lamers RJ, Burgers PC, et al. ((2009)) Quantitative matrix-assisted laser desorption ionization-fourier transform ion cyclotron resonance (MALDI-FT-ICR) peptide profiling and identification of multiple-sclerosis-related proteins. J Proteome Res 8:1404-1414.
52. Capellari S, Strammiello R, Saverioni D, Kretzschmar H, Parchi P, ((2011)) Genetic Creutzfeldt-Jakob disease and fatal familial insomnia: insights into phenotypic variability and disease pathogenesis. Acta Neuropathol 121:21-37.
53. Flechsig E, Weissmann C, ((2004)) The role of PrP in health and disease. Curr Mol Med 4:337-353.
54. Sandberg MK, Al-Doujaily H, Sharps B, Clarke AR, Collinge J, ((2011)) Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 470:540-542.